Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 5/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572304 | 0.92 | PARP15 (0.57) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL5118241 | 0.92 | PARP10 (0.57) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL9280802 | 0.91 | TDP1 (0.50) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL9280800 | 0.91 | TDP1 (0.50) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL385757 | 0.90 | PARP10 (0.58) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL11312915 | 0.89 | PARP15 (0.46) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL11312939 | 0.89 | PARP15 (0.46) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL29024848 | 0.89 | PARP15 (0.64) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL2460394 | 0.87 | TDP1 (0.68) | TDP1 | |
| SCHEMBL20870755 | 0.87 | TSHR (0.45) | PARP15PARP10PARP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| CN-118871444-A | Preparation method and application of dihydro-thienopyrimidine derivative | 上海翊石医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024179493-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | 上海翊石医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| EP-4034538-A1 | NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401968-A | Novel heterocyclic monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| WO-2021058445-A1 | NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20210094973-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3676248-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-07-08 | — | — | EP | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | ROTH GERALD JUERGEN (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079668-A1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | PARP15 2423/4885PARP10 2510/4885PARP2 3778/4885 |
| US-20210094973-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP1A1, CYP1B1 | PARP15 790/4885PARP10 1087/4885PARP2 1615/4885 |
| US-20130143876-A1 | New piperidine derivatives, pharmaceutical compositions and uses thereof | P2RX5, PIR, P2RX4 | PARP15 402/4885PARP10 967/4885PARP2 520/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | PARP15 576/4885PARP10 1176/4885PARP2 1101/4885 |
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | PARP15 3106/4885PARP10 3995/4885PARP2 3951/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | PARP15 2423/4885PARP10 2510/4885PARP2 3778/4885 |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | PARP15 1885/4885PARP10 2100/4885PARP2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.